탈회골기질 시장 : 전략적 인사이트와 예측(2026-2031년)

The Demineralized Bone Matrix Market is forecasted to grow at a 4.98% CAGR, increasing from USD 1.224 billion in 2025 to USD 1.638 billion in 2031.

The demineralized bone matrix market is undergoing significant transformation driven by the paradigm shift toward biologic augmentation in orthopedic and spinal procedures, the increasing prevalence of degenerative musculoskeletal disorders, and the growing demand for graft materials that reduce autograft harvesting morbidity. The market's evolution is characterized by the recognition that DBM products provide osteoconductive support and retain naturally occurring growth factors associated with bone healing, making them valuable alternatives to autograft in spinal fusion, trauma, and reconstructive procedures. The convergence of advanced tissue processing technologies, product formulation innovations, and integrated orthopedic portfolios is enabling more consistent, biologically active, and surgically convenient bone graft solutions. Spinal fusion surgeries, trauma fixation procedures, revision orthopedic operations, and maxillofacial reconstructions represent the primary sources of consumption, with demand closely tied to procedural volumes rather than discretionary healthcare spending. Aging populations and higher orthopedic surgery rates are expanding the addressable patient base, while product differentiation is increasingly based on handling characteristics, biological performance, and surgical workflow compatibility. The market is witnessing significant investment in product consistency, clinical evidence generation, and integration with implant portfolios, positioning DBM as a critical component of modern bone healing strategies.

Market Drivers

• The increasing spinal fusion procedure volumes represent the primary driver for the demineralized bone matrix market. Degenerative disc disease, spinal stenosis, spondylolisthesis, and deformity correction procedures continue to generate demand for bone graft materials. Surgeons increasingly seek graft options that reduce the need for autologous bone harvesting because iliac crest harvesting can increase operative time and patient morbidity. DBM products benefit from this trend because they provide biologically active graft material without requiring a second surgical site, resulting in sustained growth in DBM utilization. The growing burden of musculoskeletal disorders among aging populations is further accelerating market growth through expanded procedural demand. Population aging is increasing the incidence of osteoporosis, degenerative joint disease, vertebral disorders, and fracture-related complications. These conditions frequently require reconstructive procedures where bone healing support is clinically important. As healthcare systems manage larger elderly patient populations, demand for bone regeneration products is expected to remain closely aligned with orthopedic procedural growth. Preference for biologic augmentation in complex orthopedic procedures is driving adoption of specialized DBM formulations. Surgeons increasingly use biologic materials in revision surgeries, multi-level spinal fusions, and challenging trauma cases where bone healing may be compromised. Clinical practice has gradually shifted toward combining fixation devices with biologically active graft materials to improve fusion and healing outcomes. The expansion of outpatient orthopedic surgery is increasing demand for ready-to-use DBM putties and gels. Ambulatory surgical centers are performing a growing number of orthopedic procedures due to cost containment initiatives and improvements in minimally invasive surgical techniques. Continued investment by orthopedic and spine companies is strengthening distribution reach and increasing surgeon exposure to DBM products.

Market Restraints

• Dependence on donor tissue availability creates supply constraints. Human DBM production relies on donor bone procurement through tissue banking networks, with supply volumes influenced by donation rates, screening requirements, recovery procedures, and processing capacity. Variability in osteoinductive performance affects consistency across product lots. Differences in donor characteristics, processing techniques, sterilization methods, and preservation procedures can affect biological activity. Regulatory scrutiny of tissue-derived products increases operating costs and extends validation timelines. Human tissue products operate within stringent regulatory frameworks covering donor eligibility, processing controls, traceability, storage, and post-market surveillance. Competition from alternative graft technologies can limit pricing flexibility for DBM suppliers. Synthetic graft substitutes, ceramic-based materials, cellular bone matrices, and bone morphogenetic proteins compete for the same surgical indications. Reimbursement and cost pressures require suppliers to demonstrate both therapeutic value and cost effectiveness.

Technology and Product Insights

• The technology landscape is characterized by the growing importance of product consistency, handling characteristics, and integration with surgical workflows. Spinal fusion represents the most commercially important application segment because the procedure requires successful bone formation between vertebral segments, making graft selection a critical component of clinical outcomes. Surgeons frequently use DBM as a graft extender or graft substitute because it offers osteoconductive support and retains naturally occurring growth factors associated with bone healing. Surgeons often prioritize fusion performance, graft handling properties, radiographic assessment compatibility, and ease of placement within confined anatomical spaces. Moldable putties and gels have gained acceptance because they simplify implantation and remain positioned at the surgical site during procedures. The segment analysis reveals that competition extends beyond traditional DBM products, with cellular allografts, synthetic graft substitutes, and recombinant growth factor technologies all targeting spinal fusion procedures. Suppliers increasingly emphasize clinical evidence, product consistency, surgeon training, and integration with spinal implant systems. Human-derived DBM remains the preferred material due to established clinical acceptance and regulatory familiarity. North America represents a mature market characterized by high procedural volumes, established tissue banking infrastructure, and widespread adoption of biologic graft materials. European demand is supported by aging populations, increasing prevalence of degenerative musculoskeletal disorders, and broad access to orthopedic care. Asia Pacific healthcare investment and expanding hospital networks are supporting demand. The integration of product formulation is becoming increasingly important as manufacturers expand DBM portfolios with specialized putties, gels, pastes, and moldable graft formats designed to improve ease of implantation across different surgical applications.

Competitive and Strategic Outlook

• The competitive landscape combines multinational orthopedic manufacturers, spine specialists, tissue-processing organizations, and biologics suppliers, with market competition driven by product reliability, surgeon familiarity, regulatory compliance, distribution capabilities, and access to donor tissue resources rather than by price alone. Medtronic, Zimmer Biomet, Stryker, DePuy Synthes, SeaSpine, NuVasive, Exactech, and Straumann Group participate in adjacent orthopedic, spinal, and regenerative medicine segments that influence DBM demand. Many suppliers compete through bundled procedural solutions that combine implants, fixation systems, biologics, and surgical support services. Barriers to entry remain relatively high, with new participants required to establish donor sourcing capabilities, processing expertise, quality systems, regulatory compliance infrastructure, and surgeon relationships before achieving meaningful scale. Competitive differentiation increasingly centers on product consistency and biological performance, handling characteristics and ease of implantation, clinical evidence supporting fusion or healing outcomes, tissue sourcing and processing capabilities, regulatory compliance and traceability systems, and integration with broader orthopedic and spine portfolios. Recent key developments include Xtant Medical Holdings distributing HEMOBLAST Bellows, establishing a strong presence in the hemostatic and bone graft substitute sectors. Zimmer Biomet completed its acquisition of Paragon 28, strengthening its orthopedic reconstruction portfolio and expanding opportunities to integrate biologics into extremity procedures. Xtant Medical launched Trivium, a premium DBM allograft incorporating PureLoc Fiber Technology to provide interconnected porosity and superior biological activity. LifeNet Health unveiled PliaFX Flo, an injectable allograft that leverages a natural bone fiber formulation designed to optimize spinal fusion handling properties.

Short Conclusion

• The demineralized bone matrix market is positioned for steady growth driven by the convergence of spinal procedure volumes, aging demographics, and biologic augmentation preferences. The transition from autograft harvesting toward ready-to-use biologic graft materials represents a fundamental shift in bone healing strategies. While challenges related to tissue availability, product variability, and regulatory compliance persist, strategic investments in processing capabilities, clinical evidence, and surgical integration are creating durable competitive advantages for market leaders. The long-term market outlook remains positive, with DBM evolving into a critical component of orthopedic and spinal procedures, supporting fusion success, bone healing, and improved patient outcomes across global healthcare systems.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2031
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. DEMINERALIZED BONE MATRIX MARKET BY PRODUCT

• 5.1. Introduction
• 5.2. Gel
• 5.3. Putty
• 5.4. Paste
• 5.5. Graft
• 5.6. Others

6. DEMINERALIZED BONE MATRIX MARKET BY MATERIAL

• 6.1. Introduction
• 6.2. Human DBM
• 6.3. Animal DBM
• 6.4. Synthetic DBM

7. DEMINERALIZED BONE MATRIX MARKET BY APPLICATION

• 7.1. Introduction
• 7.2. Spinal Fusion
• 7.3. Dental / Maxillofacial Surgery
• 7.4. Trauma Surgery
• 7.5. Joint Reconstruction
• 7.6. Others

8. DEMINERALIZED BONE MATRIX MARKET BY END-USER

• 8.1. Introduction
• 8.2. Hospitals
• 8.3. Orthopedic Clinics
• 8.4. Ambulatory Surgical Centers
• 8.5. Others

9. DEMINERALIZED BONE MATRIX MARKET BY GEOGRAPHY

• 9.1. Introduction
• 9.2. North America
  • 9.2.1. By Product
  • 9.2.2. By Material
  • 9.2.3. By Application
  • 9.2.4. By End-User
  • 9.2.5. By Country
    • 9.2.5.1. USA
    • 9.2.5.2. Canada
    • 9.2.5.3. Mexico
• 9.3. South America
  • 9.3.1. By Product
  • 9.3.2. By Material
  • 9.3.3. By Application
  • 9.3.4. By End-User
  • 9.3.5. By Country
    • 9.3.5.1. Brazil
    • 9.3.5.2. Argentina
    • 9.3.5.3. Others
• 9.4. Europe
  • 9.4.1. By Product
  • 9.4.2. By Material
  • 9.4.3. By Application
  • 9.4.4. By End-User
  • 9.4.5. By Country
    • 9.4.5.1. United Kingdom
    • 9.4.5.2. Germany
    • 9.4.5.3. France
    • 9.4.5.4. Spain
    • 9.4.5.5. Others
• 9.5. Middle East and Africa
  • 9.5.1. By Product
  • 9.5.2. By Material
  • 9.5.3. By Application
  • 9.5.4. By End-User
  • 9.5.5. By Country
    • 9.5.5.1. Saudi Arabia
    • 9.5.5.2. UAE
    • 9.5.5.3. Others
• 9.6. Asia Pacific
  • 9.6.1. By Product
  • 9.6.2. By Material
  • 9.6.3. By Application
  • 9.6.4. By End-User
  • 9.6.5. By Country
    • 9.6.5.1. China
    • 9.6.5.2. Japan
    • 9.6.5.3. India
    • 9.6.5.4. South Korea
    • 9.6.5.5. Taiwan
    • 9.6.5.6. Others

10. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 10.1. Major Players and Strategy Analysis
• 10.2. Market Share Analysis
• 10.3. Mergers, Acquisitions, Agreements, and Collaborations
• 10.4. Competitive Dashboard

11. COMPANY PROFILES

• 11.1. Medtronic plc
• 11.2. Zimmer Biomet Holdings, Inc.
• 11.3. Stryker Corporation
• 11.4. DePuy Synthes
• 11.5. Exactech, Inc.
• 11.6. SeaSpine Holdings Corporation
• 11.7. Straumann Group
• 11.8. NuVasive, Inc.

12. APPENDIX

• 12.1. Currency
• 12.2. Assumptions
• 12.3. Base and Forecast Years Timeline
• 12.4. Key benefits for the stakeholders
• 12.5. Research Methodology
• 12.6. Abbreviations